Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
QNCX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $2.45
Previous CloseN/A
Volume30.57K
Average Volume (3M)451.03K
Market Cap
$48.20M
Enterprise Value$53.60M
Total Cash (Recent Filing)$40.78M
Total Debt (Recent Filing)$14.81M
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Aug 12, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding45,468,780
10 Day Avg. Volume188,837
30 Day Avg. Volume451,031
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-1.40
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue194.22
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$6.67Price Target Upside535.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Quince Therapeutics News
PremiumCompany Announcements
Quince Therapeutics Reports Q1 2025 Results and Strategic Updates
PremiumStock Analysis & Ideas
Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Quince Therapeutics Reports 2024 Financial Results and Trial Progress
Bulls Say, Bears Say
Bulls Say
Financial StabilityQuince Therapeutics has sufficient cash to fund operations into early 2026, supporting its financial stability and ongoing research and development efforts.
Innovation In TreatmentThe AIDE technology used by Quince allows for a simple and safe point-of-care treatment, which is beneficial for patients avoiding daily steroid side effects.
Trial ExecutionThe P3 NEAT trial is operationally well-executed with limited withdrawals and low rates of missing data and procedural deviations.
Bears Say
Enrollment ChallengesEnrollment in the P3 NEAT study is slower than expected, which has led management to consider concluding enrollment early.
Financial PerformanceQuince reported 4Q24 and 2024 results with a net loss of ($12.5M) and ($56.8M), respectively, which included $25.4M in non-cash items.
Ownership Overview
18.04% Insiders
3.82% Mutual Funds
2.35% Other Institutional Investors
72.72% Public Companies and Individual Investors
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.51 and its highest was $2.45 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $48.20M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Aug 12, 2025 which is in 69 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on May 13, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.228 by -$0.112.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 45,468,780 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.228. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
Quince Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (535.24% Upside)
$6.67 (535.24% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 302.8%
Last 30 Days ▲ 302.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.71%
12-Months-Change
Fundamentals
Return on Equity
-130.90%
Trailing 12-Months
Asset Growth
-32.77%
Trailing 12-Months
Company Description
Quince Therapeutics
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
QNCX Stock 12 Month Forecast
Average Price Target
$6.67
▲(535.24%Upside)
Technical Analysis
Agenus
―
Cyclacel Pharmaceuticals
―
Fortress Biotech
―
Outlook Therapeutics
―
Immix Biopharma
―